Sandoz Boss Warns There’s a Climate Cost of Obesity Wonder Drugs

Richard Saynor wants to transform Sandoz Group AG into a world champion in copying leading-edge drugs, including anti-obesity and biological treatments, with the goal of bringing them to the masses.

After leading Europe’s largest generics company through a spinoff from Novartis AG last year, the chief executive officer has nearly doubled Sandoz’s share price. The 57-year-old Brit rejoined Basel-based Sandoz in 2019 after leaving for GSK nearly a decade earlier.